再鼎医药 is a globally integrated innovative biopharmaceutical company focused on patient-centered solutions, providing therapies for cancer, autoimmune diseases, infectious diseases, and central nervous system disorders.

再鼎医药

Zai Lab | 25,300 followers on LinkedIn. Delivering innovative, transformational outcomes to patients around the world  | Zai Lab is an innovative, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing transformative products that address medical conditions with significant unmet patient needs in the areas of oncology, autoimmune disorders, infectious diseases and neurological disorders. Our goal is to leverage our capabilities and resources to reach one million patients by 2030, positively impacting human health worldwide.

Talent Acquisition Leader

Brent Eberle

Carol Brugger

Senior Vice President, Investor Relations at Zai Lab

Christine Chiou

Chief Financial Officer at Zai Lab | Strategic Finance Business Partner | Biopharmaceutical Industry

Yajing Chen, PhD

Zai Lab

This week we announced our #financial results for the third quarter of 2024, along with recent product highlights and corporate updates. Learn more: https://bit.ly/3Z0pyBM #innovation #biotech #healthcare #Q3Results #investors

#ICYMI : Data from the ongoing global Phase 1 study of our investigational DLL3-targeted antibody-drug conjugate were featured in several news outlets, including Endpoints News , FirstWord Pharma and Cancer Network . To read more about how we’re continuing to develop a potential best-in-class, next-generation #ADC , visit https://bit.ly/3UoeXhv #innovation #SCLC #lungcancer #cancernews #oncology

Today on #WorldPsoriasisDay , and every day, we stand with the global community to raise awareness and fight stigma associated with this autoimmune disorder. At Zai Lab, we are committed to advocating for better understanding and #innovative treatment options for people living with #psoriasis . To learn more about the public health impact of psoriasis, check out the World Health Organization ’s global report: https://bit.ly/3UPbQiX

Today we presented data on Zai Lab’s investigational antibody drug conjugate ( #ADC ) that demonstrates promising objective response rates and safety profile in extensive-stage small-cell lung cancer. To learn more about this important step in the development of our global #oncology pipeline, please visit: https://bit.ly/3UoeXhv #ENASymp24 #innovation #healthcare #biotech

Three years into our Trust for Life program, Zai Lab is resolute in our commitments to improving human health, creating better outcomes, and acting right now. Zai Lab's 2023 Trust for Life Report illustrates our achievements toward our commitments and establishes future goals, including by maintaining gender equity in leadership and pay, and reaching one million patients by 2030. Explore our commitment to responsible corporate sustainability: https://bit.ly/4dArCob #Healthcare #Biotech #innovation #Sustainability #ESG

#NEWS : Zai Lab will be presenting data from the Phase 1 study of our investigational antibody-drug conjugate for DLL3+ solid tumors. The oral presentation at the EORTC-NCI-AACR Symposium will discuss the potential of ZL-1310 as an innovative #ADC in the treatment of small cell lung cancer. Read more about this data and our growing internally developed global #oncology pipeline: https://bit.ly/3Uro3Kv #ENASymp24 #SCLC #oncology #innovation #cancerresearch

Congratulations to our partner Bristol Myers Squibb on yesterday's FDA approval. We join in the goal of improving outcomes for people with #schizophrenia worldwide. #mentalhealth #innovation #healthcare #biotech

We are thrilled to welcome Dr. Prista Charuworn to Zai Lab as Vice President, Immunology, Global R&D. She is responsible for leading and advancing research and development #strategy for our #immunology therapeutic area, as well as our #neuroscience and infectious disease assets. Read more about Dr. Charuworn's extensive experience and leadership in clinical development and global product strategy: https://bit.ly/4do1b4U #WelcomeToTheTeam #innovation

Last week, our Chief Medical Officer of Oncology Robert J. Brown, MD represented Zai Lab at the 2024 ESMO - European Society for Medical Oncology Congress. Read more about our internal global #oncology pipeline and data presented on anticancer immune response in advanced solid tumors: https://bit.ly/3X4lNcf #ESMO24 #innovation #healthcare #cancer #immunotherapy

#NEWS : Zai Lab is presenting data at the #EADV 2024 Congress from a preclinical trial showing the potential of a bispecific antibody for the treatment of moderate-to-severe atopic #dermatitis . This data represents advancement in the development of Zai Lab’s internal pipeline. To read more, visit https://bit.ly/47xvMM0 #EADVCongress #dermatology #healthcare #innovation #biotech

Metric
Company Name	再鼎医药
Symbol
MSH ID	COM:ZAILABORATORY:CN
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biopharmaceuticals
Country	CN
Stage	Post-IPO Equity
Employee Count
Website	cn.zailaboratory.com
LinkedIn	zai-lab
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	4.14K
Web Traffic Growth	-0.39
Valuation
Raised Capital	857.50M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ZAIL

COM:ZAILABORATORY:CN

再鼎医药

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue